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Objectives: Stereotactic body radiation therapy (SBRT) yields excellent disease control for
low- and intermediate-risk prostate cancer by delivering high doses of radiation in a small
number of fractions. Our report presents a 7-year update on treatment toxicity and quality
of life (QOL) from 515 patients treated with prostate SBRT.
Methods: From 2006 to 2009, 515 patients with clinically localized, low-, intermediate-,
and high-risk prostate cancer were treated with SBRT using Cyberknife technology. Treat-
ment consisted of 35–36.25 Gy in 5 fractions. Seventy-two patients received hormone
therapy. Toxicity was assessed at each follow-up visit using the expanded prostate cancer
index composite (EPIC) questionnaire and the radiation therapy oncology group urinary and
rectal toxicity scale.
Results: Median follow-up was 72 months. The actuarial 7-year freedom from biochemical
failure was 95.8, 89.3, and 68.5% for low-, intermediate-, and high-risk groups, respectively
(p<0.001). No patients experienced acute Grade 3 or 4 acute complications. Fewer than
5% of patients had any acute Grade 2 urinary or rectal toxicity. Late toxicity was low, with
Grade 2 rectal and urinary toxicity of 4 and 9.1%, respectively, and Grade 3 urinary toxicity
of 1.7%. Mean EPIC urinary and bowel QOL declined at 1 month post-treatment, returned
to baseline by 2 years and remained stable thereafter. EPIC sexual QOL declined by 23%
at 6–12 months and remained stable afterwards. Of patients potent at baseline evaluation,
67% remained potent at last follow-up.
Conclusion:This study suggests that SBRT, when administered to doses of 35–36.25 Gy,
is efficacious and safe. With long-term follow-up in our large patient cohort, we continue
to find low rates of late toxicity and excellent rates of biochemical control.
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INTRODUCTION
Several recent studies on stereotactic body radiotherapy (SBRT)
for prostate cancer have been published, providing evidence of
excellent biochemical disease control with short-term follow-up
(1–6). With follow-up of up to 5 years, reported bowel and bladder
toxicity has been quite low,and quality of life (QOL) measures have
been favorable (7). However, the likelihood of long-term toxicity is
not well known, and more studies with longer follow-up are nec-
essary in order to confirm initial reports. As a result, the adoption
of prostate SBRT in the clinic has proceeded slowly, though it has
recently been accepted by both the American society for radiation
oncology (ASTRO) and the national comprehensive cancer net-
work (NCCN). The purpose of our study is to document incidence
of bowel, bladder, and sexual toxicity and QOL in a large cohort
of patients, with follow-up as long as 8 years. This represents
significantly longer follow-up than previously published.
MATERIALS AND METHODS
PATIENT SELECTION
Between 2006 and 2009, 515 consecutive patients with newly diag-
nosed, non-metastatic, biopsy-proven prostate cancer were treated
with SBRT. The first 15 patients were treated on an IRB-approved
in-house protocol, and the remainder was treated off protocol,
with similar treatment parameters. All patients were consented
for treatment and agreed to use of follow-up data for research
purposes. Patients were stratified into D’Amico risk groups (low-
risk: PSA< 10 and Gleason sum of 6 and clinical stage T1c–T2a,
intermediate-risk: PSA 10–20 or Gleason sum of 7 or clinical stage
T2b, high risk: PSA> 20 or Gleason sum of 8–10 or clinical stage
T2c or higher). Seventy-two patients received androgen depriva-
tion therapy (ADT) prior to and during treatment,at the discretion
of the urologist.
TREATMENT
Fiducial-based image-guided SBRT was delivered using the
CyberKnife system (Accuray Inc., Sunnyvale, CA, USA), G3
model with multiplan 2.0. The treatment specifics of Cyberknife
have been published previously (8). General techniques are out-
lined here. Four gold fiducials were placed transperineally with
ultrasound guidance into the prostate. This was followed by a
non-contrast CT scan in the supine position, with alpha cradle
immobilization. CT scan was obtained using a 64 slice CT scanner
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with 1.25 mm slices. Unless contraindicated, patients underwent
prostate MRI, and images were fused to CT images in order to
better visualize the inferior portion of the prostate. No urinary
catheter was used. Dose was prescribed to the planning target vol-
ume (PTV), which consisted of a 5 mm expansion on the prostate,
reduced to 3 mm posteriorly. Homogeneous planning was per-
formed, and dose normalized to the 83–87% isodose line, with
full prescription dose covering at least 95% of the PTV. Anatom-
ical contours of the prostate, seminal vesicles, rectum, bladder,
penile bulb, femoral heads, and testes were generated and dose
volume histograms (DVH) constructed. The urethra was not con-
toured as no constraints were placed on it. Rectal DVH goals were
V50< 50% (i.e., the volume receiving 50% of the prescribed dose
was <50%), V80< 20, V90< 10, and V100< 5%. The bladder
DVH goals were V50< 40 and V100< 10%. A typical D50 for
the bladder and rectum was 40–45% of the maximum dose. The
femoral head DVH goal was V40< 5%.
During a typical 45-min treatment, fiducial seeds were tracked
and positional adjustments made at 30–60 s intervals. Every morn-
ing prior to SBRT, patients underwent bowel prep with Dulcolax®
(Boehringer Ingelheim, Germany) and a Fleet® Enema (C.B. Fleet
Company, Inc., Lynchburg, VA, USA). In addition, all patients
received 1500 mg of amifostine (MedImmune, LLC, Gaithersburg,
MD, USA), mixed in saline and instilled into the rectum approx-
imately 15–20 before treatment (9). The radiation dose was 35
(n= 158) or 36.25 (n= 357) Gy in 5 fractions, given daily. The
first 50 patients treated received 35 Gy. After a report from Stanford
documenting the feasibility of using 36.25 Gy (10), we increased
the dose accordingly for the next 30 months. Dose was reduced
back to 35 Gy due to increased toxicity.
FOLLOW-UP
The median follow-up for the entire cohort was 72 months. PSAs
were obtained at baseline. Post-treatment, PSA was obtained at
3 months post-treatment intervals for the first 2 years, and at
6 months intervals thereafter. The Phoenix definition (nadir+ 2)
was used to define relapse (11).
Urinary, sexual, and bowel QOL expanded prostate cancer
index composite (EPIC) scores (12) were obtained from patients
at baseline, 3 weeks post-treatment, and subsequently every 3–
6 months for the first 2 years, then 12 months. Acute and late bowel
and bladder toxicity was scored according to the criteria set forth
by radiation therapy oncology group (RTOG) (13).
STATISTICAL ANALYSES
Actuarial biochemical control was calculated using the Kaplan–
Meier method and log-rank analysis performed. The likelihood
ratio test was used to determine differences in toxicity. Cox multi-
variate regression analysis was used to analyze the patient factors
associated with development of Grade 2–3 late urinary toxicity.
RESULTS
PATIENT CHARACTERISTICS
Patient characteristics are summarized in Table 1. The median
follow-up for all patients was 72 months (range, 0–96 months), 26
patients had follow-up for as long as 96 months.
Using D’Amico risk stratification, 324 patients were low-risk,
153 were intermediate-risk, and 38 were high-risk. Median patient
Table 1 | Patient characteristics.
Age at diagnosis Years
Mean 68.5 (43.8–89.2)
Median 69.0 (43.8–89.2)
Age at diagnosis Number of patients Percent of patients
40–49 4 0.7
50–59 77 15.0
60–69 201 39.0
70–79 196 38.1
80–89 37 7.2
PSA level at treatment ng/mL
Combined mean (range) 6.6 (1.0–42.9)
Median 5.4
PSA level at diagnosis Number of patients Percent of patients
<4 ng/mL 83 16.1
4–10 ng/mL 368 71.5
>10–20 ng/mL 64 12.4
Risk Category
Low 324 62.9
Intermediate 153 29.7
High 38 7.4
Clinical Stage
T1a 2 0.4
T1c 462 89.7
T2a 51 9.9
Gleason Score
6 357 69.3
7 (3+4) 84 16.3
7 (4+3) 42 8.2
8 (4+4) 24 4.7
9 (4+5) 6 1.1
9 (5+4) 2 0.4
Hormone Treatment
No 443 86.0
Yes 72 14.0
RT Treatment
35 Gy 158 30.7
36.25 Gy 357 69.3
age was 69.5 (range, 43.8–89.3 years). The median PSA at diagnosis
was 5.4 ng/mL. At last follow-up, 59 patients were deceased, none
from prostate cancer. There were 13 deaths in the 35 Gy group and
46 deaths in the 36.25 Gy group, none attributable to prostate can-
cer. Seventy-two patients received ADT. Of this group, 26 patients
were low-risk, 25 were intermediate-risk, and 21 were high-risk.
ACUTE TOXICITY
All patients were seen at 3 weeks and 3 months post-treatment. At
each visit, patients were assessed for bowel and bladder toxicity
using RTOG criteria. Overall, 4% of patients reported Grade 2
urinary or bowel toxicity. Of patients who received 35 Gy, Grade
1 and Grade 2 urinary toxicity was 72 and 4%, respectively, and
Grade 1 and Grade 2 rectal toxicity was 76 and 4%, respectively.
There was no Grade 3–4 toxicity observed.
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FIGURE 1 | Genitourinary toxicity by dose.
Of patients who received 36.25 Gy, Grade 1 and Grade 2 uri-
nary toxicity was 74 and 4%, respectively, and Grade 1 and Grade
2 rectal toxicity was 78 and 4%, respectively. There was no sig-
nificant difference in the incidence of early toxicity for the two
doses used.
LATE TOXICITY – SEXUAL POTENCY
Patients were assessed for sexual potency prior to start of treat-
ment, 375 out of 515 patients reported themselves to be potent. Of
this group, 252 (67.2%) remained potent at last follow-up, with
25% requiring medication. Of the 375 patients initially potent at
baseline, 37 received ADT, and only 14 out of 37 (38%) remained
potent at last follow-up. In contrast, 338 patients who were potent
at baseline did not receive ADT, and 239 out of 338 (70.7%)
remained potent at last follow-up. The difference was statistically
significant, p< 0.001.
LATE TOXICITY – URINARY
Grade 2 urinary toxicity (mostly severe dysuria, urgency, or
obstructed flow) occurred in 47 (9.1%) patients. Of the 158
patients who received 35 Gy, 9 (5.7%) had Grade 2 urinary toxic-
ity. In comparison, of the 357 patients who received 36.25 Gy, 38
(10.6%) developed Grade 2 urinary toxicity (Figure 1). Grade
3 toxicity was significantly higher after 36.25 Gy compared to
35 Gy (p= 0.005), as was the overall incidence of Grade 2 or
higher toxicity (p= 0.05). Late Grade 3 toxicity occurred in nine
patients (1.7%) and consisted of either urinary retention requiring
surgery or bleeding requiring laser coagulation. All Grade 3 events
occurred in patients who received 36.25 Gy.
The median time to development of late urinary toxicity was
18 months (range, 6–60 months). Only 5 of 47 patients (11%)
developed urinary toxicity after 36 months. At last follow-up, 37
of the 47 patients had complete resolution of their symptoms.
FIGURE 2 | Gastrointestinal toxicity by dose.
LATE TOXICITY – GASTROINTESTIONAL
Late Grade 2 bowel toxicity occurred in 21 (4%) of patients.
Of this group, five patients were on anticoagulation therapy
with Coumadin. Most common manifestation was rectal bleed-
ing (85.7%). Grade 2 toxicity occurred in 3.2% (n= 5) and 4.5%
(n= 16) of patients who received 35 and 36.25 Gy, respectively
(Figure 2). This difference was not significant (p= 0.48). There
was no Grade 3–4 bowel toxicity noted. The median time to devel-
opment of bowel toxicity was 18 months (range, 6–44 months).
At last follow-up (median follow-up= 72 months), 19 of the 21
affected patients experienced resolution of their symptoms.
PROSTATE VOLUME
Data on prostate volume were available for 336 patients. Median
prostate volume was 59.15 cc (16.8–224 cc), and mean prostate
volume was 65.3 cc (SD= 30.2 cc). Patients were analyzed based
on prostate volume greater than or less than 60 cc, 173 patients
had prostate volume ≤60 cc versus 163 with prostate volume
>60 cc. There was higher incidence of both Grade 2 (n= 19,
11.6%) and Grade 3 (n= 5, 3.1%) toxicity in patients with
prostate volume >60 cc, compared to Grade 2 (n= 12, 6.9%)
and Grade 3 (n= 1, 0.6%) toxicity in patients with prostate vol-
ume ≤60 cc, this trended toward significance (p= 0.051). There
was no significant difference in GI toxicity between patients
with prostate volume >60 cc (Grade 2 toxicity n= 7, 4.3%) ver-
sus those with prostate volume ≤60 cc (Grade 2 toxicity n= 6,
3.7%).
QUALITY OF LIFE – EPIC QUESTIONNAIRE
Prior to treatment, all patients completed the initial EPIC ques-
tionnaire to evaluate urinary, bowel, and sexual QOL. At each
subsequent time points, patients were requested to fill out the
EPIC questionnaire to assess follow-up QOL, but not all patients
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FIGURE 3 | Expanded prostate cancer index composite urinary scores.
The mean EPIC score is depicted for each time point. A number of patients
with completed questionnaires are shown in table below.
FIGURE 4 | Expanded prostate cancer index composite bowel scores.
The mean score is depicted for each time point. A number of patients with
completed questionnaires are shown in table below.
were compliant. Mean scores for all three domains, with the num-
ber of patients responding at each follow-up interval, is depicted in
Figures 3–5. For urinary (Figure 3) and bowel (Figure 4) domains,
mean EPIC scores decreased acutely and then gradually rose back
to baseline by one year. After 1 year, mean EPIC scores extending
out to 8 years did not differ significantly from baseline. EPIC sexual
QOL (Figure 5) declined by 23% at 6–12 months and remained
stable, 67% of the patients potent at baseline remained potent at
last follow-up.
There was no significant difference in EPIC bowel, sexual, or
urinary scores between 35 or 36.25 Gy at any time point.
MULTIVARIATE ANALYSIS
On univariate analysis, prostate size >60 cc was found to be a
significant (p= 0.03) predictor of Grade 2 or higher late GU tox-
icity (Table 2). Using a higher dose trended toward significance
FIGURE 5 | Expanded prostate cancer index composite sexual scores.
EPIC sexual scores are reported as a percentage of each respective
patient’s baseline score. A number of patients with completed
questionnaires are shown in table below.
Table 2 | Univariate (UVA) and multivariate (MVA) logistic regression
analyses looking at patient characteristics and the effect on Grade 2
or higher late GU toxicity.
Factor UVA MVA
p p RR (95% CI)
Prostate size (above or
below 60 cc)
0.03 0.03 0.86 (0.66–1.13)
Dose (35 versus 36.25 Gy) 0.051 <0.0001 3.31 (2.17–5.35)
Baseline GU EPIC score
(above or below 90)
0.39 0.58 0.93 (0.71–1.21)
(p= 0.051), whereas baseline GU EPIC score was not significant.
Multivariate analysis was performed looking at these three vari-
ables. Dose of 36.25 versus 35 Gy was the only significant variable,
with p< 0.0001 (RR 3.31, 95% CI 2.17–5.35).
BIOCHEMICAL CONTROL AND PSA
Actuarial 7-year biochemical recurrence-free survival 95.6, 89.6,
and 68.5% was 95.6% for low-risk, 89.6% for intermediate-risk,
and 68.5% for high-risk patients (Figure 6).
For low- and intermediate-risk patients, there was no sig-
nificant difference in biochemical disease-free survival (bDFS)
between 35 versus 36.25 Gy (p= 0.36).
DISCUSSION
This study has the longest toxicity and QOL follow-up to date for
prostate SBRT, and as a result, several important questions can
begin to be addressed. The first question is whether SBRT doses
of 35–36.25 Gy can be well-tolerated. Prior reports on SBRT, with
only several years follow-up, reported excellent QOL outcomes but
raised skepticism that late toxicity events would occur after many
years. Our results suggest that the incidence of bowel and bladder
toxicity continues to remain low, even after extended follow-up.
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FIGURE 6 | Biochemical disease-free survival.
Interestingly, over 90% of toxicity events occurred within 3 years
of treatment, suggesting that the incidence of late toxicity will
continue to remain low as more follow-up is obtained. Our low
toxicity and excellent QOL are comparable or lower than results
published for HDR and LDR brachytherapy, proton beam, and
dose-escalated IMRT (14–17).
The low toxicity is consistent with radiobiologic data suggesting
that prostate cancer has a very low α/β ratio, whereas the normal
bowel/bladder tissue has α/β ratio of 3 (18), making hypofraction-
ation a logical treatment choice. Assuming α/β ratio of 3 (18) for
late soft tissue complications, the radiation doses used in this study
of 35–36.25 Gy are equivalent to delivering 70–77 Gy at 1.8 Gy per
fraction to surrounding normal tissue, this is lower than the dose
to normal tissues delivered using standard IMRT. In addition, the
ability to utilize tighter margins for SBRT treatment allows for
more favorable bladder and rectum DVHs, and translates to mild
bowel and bladder toxicity in both the short- and long-term.
In a recent well-publicized article by Yu et al (19), it has been
suggested that SBRT may cause more urinary side effects than
IMRT. Our data show a toxicity profile and QOL that compares
favorably to IMRT. For instance, our overall rate of 9% Grade 2
urinary toxicity is comparable to Zelefsky’s report of 9% Grade 2
toxicity in 2006 (20). In fact, our rate of 5.7% late Grade 2 toxicity
with 35 Gy, with no Grade 3 events, is arguably better than IMRT
(21). Although it is not known, it is likely that patients treated to
higher doses were included in the study by Yu. Based on our find-
ings, which suggest 36.25 Gy results in greater toxicity than 35 Gy,
we surmise that higher doses will result in even greater rates of
toxicity, and likely account for Yu’s findings.
Our study also begins to address the question of appropriate
SBRT dose. We noted a significant increase in urinary toxicity as
the dose rises from 35 to 36.25 Gy. This is equivalent to normal
tissue EQD increase from 70 to 77 Gy. Delivering 35 Gy in 5 frac-
tions is equivalent to 200 Gy BED to the tumor cells, and studies
suggest going higher than this dose does not result in better dis-
ease control (22). As a result, we hypothesize that 35 Gy may be
the optimal dose for low- and intermediate-risk prostate cancer,
and higher doses may result in increased toxicity without increased
biochemical control. Recently, published studies on prostate SBRT,
documenting unacceptably high rates of toxicity with higher radi-
ation doses, are consistent with this hypothesis (23), and merits
further study. Of note, the current RTOG 0938 trial is treating
patients to dose of 36.25 in 5 fractions, and our data suggest that
there may be greater toxicity with this higher dose.
Despite the higher toxicity noted in patients treated to 36.25 Gy,
the QOL data did not reflect any disparity between the two groups
by dose. Most bowel and bladder toxicity resolved with time and
symptomatic treatment; as a result, QOL was not impacted for sig-
nificant lengths of time and in most cases had returned to patient
baseline once toxicity resolved. We believe this likely explains why
QOL data between the two doses remained similar, whereas RTOG
toxicity was significantly higher in the 36.25 Gy patient cohorts
though the incidence of toxicity was greater with the higher dose.
The potential impact of prostate size and pre-treatment urinary
function on long-term urinary toxicity has been an interesting
question for study. To address this, a multivariate analysis was
performed, and neither gland size nor impaired baseline urinary
QOL predicted for late GU toxicity. These results are reassuring
and suggest large prostate size and baseline poor urinary function
should not automatically preclude patients from being considered
for SBRT.
Regardless of dose, rectal toxicity remained quite mild. We do
not believe the low rate of rectal toxicity can be attributed to the
use of amifostine. Other groups have published reports on their
prostate SBRT experience, and have also found low toxicity with-
out the use of Amifostine (1, 3, 8). In fact, in our clinic, use of
Amifostine was discontinued since early 2010, and thus far, we
have not observed any increases in rectal toxicity.
Finally, we report encouraging potency preservation rates, with
67% of initially potent at baseline able to retain good function.
This is similar to outcomes for HDR brachytherapy (16) and more
favorable than outcomes reported for dose-escalated IMRT (15).
In fact, potency preservation rates after SBRT are only slightly
worse than what one would expect in a similar cohort of men in
this age group, who did not receive any radiotherapy (24). The
decrease in potency is reflected in the overall reduction of sexual
QOL scores. Since no significant difference in sexual QOL was
observed between the doses used, we postulate this is due to the
tight constraints to the penile bulb that were utilized for both
doses, and conjecture that penile bulb dose may be an important
predictor of potency preservation.
It should be noted that we delivered all treatments daily (QD),
Monday through Friday. King suggested in his 2009 article that
every other day (QOD) treatments to 36.25 Gy yields less rectal
toxicity, compared to QD (10). He reported 18% Grade 2 rec-
tal toxicity in patients treated QD, significantly higher than our
findings, which suggests that there may have been a dosimetric
issue with these early patients. In a more recent 2012 update (1),
he found a lower rate of Grade 1 rectal and urinary toxicity with
QOD compared to QD, but no significant difference in Grade 2–3.
In addition, his total number of patients is fairly low at 67, making
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it difficult to draw any definitive conclusions. Therefore, contrary
to popular belief, we feel it is not established that QOD treatments
yield less rectal or urinary toxicity. Particularly with treatment
delivered daily to 35 Gy, we shown very low rates of Grade 2–3
toxicity, with high efficacy. Our data, with many more patients,
suggest that dose, rather than the schedule, is the most important
predictor of late rectal toxicity.
Prostate SBRT has the added advantages of patient convenience
and decreased healthcare cost. Only 5 treatment visits are required,
in contrast to 40–45 for conventionally fractionated radiation.
Furthermore, the current Medicare rate is substantially lower for
prostate SBRT, which costs $21,000 in contrast to $32,000 for
IMRT and $53,000 for protons.
CONCLUSION
Cyberknife SBRT produces excellent long-term biochemical con-
trol rates with acceptably low rates of long-term toxicity, similar to
other radiotherapy modalities. Our results suggest that 35 Gy is as
effective as 36.25 Gy for low- and low-intermediate-risk patients,
and has significantly less late Grade 2–3 urinary toxicity. Further
follow-up extending beyond 10 years will be obtained to deter-
mine the durability of response and incidence of late toxicity. Both
prospective and randomized studies are indicated to confirm these
encouraging results.
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